Gabelli Funds’s Veracyte VCYT Stock Holding History

Gabelli Funds’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-49,700	Closed	-$625K	–	1169
2018 Q4	$625K	Sell	49,700 -50,300	-50%	-$595K	﹤0.01%	936
2018 Q3	$955K	Buy	+100,000	New	+$1.1M	0.01%	912

Other funds holding VCYT

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gabelli Funds's VCYT Position: Q1 2019 in Review

Gabelli Funds sold out of Veracyte (VCYT) in Q1 2019, closing a stake of 49,700 shares — an estimated $625K sold.

Gabelli Funds first reported a position in VCYT in Q3 2018 and held it in 2 quarters. The position peaked at $955K in Q3 2018. 149 funds tracked by Wall St. Rank hold VCYT as of Q1 2019.

Gabelli Funds reported no remaining Veracyte position as of Q1 2019 after selling out during the quarter.
Gabelli Funds sold 49,700 Veracyte shares in Q1 2019, an estimated $625K.
Gabelli Funds first reported a position in Veracyte in Q3 2018 and held it in 2 quarters.
Gabelli Funds's Veracyte position peaked at $955K in Q3 2018.
149 funds tracked by Wall St. Rank held Veracyte as of Q1 2019.

Based on Gabelli Funds's 13F filing for Q1 2019, filed 2 May 2019.